title: [Infection and sepsis prevention in prostate biopsy].
abstract: Prostate biopsy is currently the gold standard in the diagnosis of carcinoma of the prostate. An estimated one million prostate biopsies are performed every year in Europe. Worldwide the most frequent form is the transrectal prostate biopsy using preoperative fluoroquinolone prophylaxis. In recent years an increasing rate of infectious complications after prostate biopsy has been observed. The main causative factor is fecal fluoroquinolone-resistant bacteria. This review aims to present the current evidence regarding infectious complications after prostate biopsy and strategies to reduce symptomatic infections and urosepsis.
authors.affiliation: Klinik für Urologie, Kinderurologie und Andrologie, Universitätsklinikum Giessen und Marburg GmbH, Standort Giessen, Justus-Liebig-Universität, Rudolf-Buchheim-Str. 7, 35392, Giessen, Deutschland, Wagenlehner@AOL.com.
authors.forename: F M E
authors.initials: FM
authors.lastname: Wagenlehner
authors.forename: A
authors.initials: A
authors.lastname: Pilatz
authors.forename: P
authors.initials: P
authors.lastname: Waliszewski
authors.forename: T
authors.initials: T
authors.lastname: Dansranjavin
authors.forename: W
authors.initials: W
authors.lastname: Weidner
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000209:etiology / Q000517:prevention & control*; D001707:Biopsy, Needle / Q000009:adverse effects*; D019317:Evidence-Based Medicine; D006801:Humans; D008297:Male; D011292:Premedication / Q000379:methods*; D011471:Prostatic Neoplasms / Q000150:complications / Q000473:pathology*; D018805:Sepsis / Q000209:etiology / Q000517:prevention & control*; D014552:Urinary Tract Infections / Q000209:etiology / Q000517:prevention & control*
chemical_list: D000900:Anti-Bacterial Agents
references.citation: Urology. 1991 Jul;38(1):84-7
references.pmid: 1866869
references.citation: World J Urol. 2012 Feb;30(1):39-50
references.pmid: 21779836
references.citation: J Urol. 2010 Mar;183(3):963-8
references.pmid: 20089283
references.citation: Int J Antimicrob Agents. 2005 Jul;26(1):1-7
references.pmid: 15970433
references.citation: Eur Urol. 2012 Jun;61(6):1110-4
references.pmid: 22244150
references.citation: Br J Urol. 1982 Oct;54(5):550-1
references.pmid: 6983378
references.citation: Int Urol Nephrol. 2012 Aug;44(4):1055-63
references.pmid: 22371127
references.citation: Infection. 1991 Jan-Feb;19(1):30-5
references.pmid: 1707399
references.citation: Urologe A. 2011 Nov;50(11):1469-78; quiz 1479-80
references.pmid: 21997660
references.citation: BJU Int. 2012 Jun;109(12):1781-5
references.pmid: 22040349
references.citation: J Urol. 2012 Apr;187(4):1275-9
references.pmid: 22341272
references.citation: J Urol. 2011 Nov;186(5):1830-4
references.pmid: 21944136
references.citation: Int J Antimicrob Agents. 2013 Mar;41(3):267-71
references.pmid: 23313536
references.citation: Cochrane Database Syst Rev. 2011 May 11;(5):CD006576
references.pmid: 21563156
references.citation: Int J Urol. 1998 May;5(3):243-6
references.pmid: 9624555
references.citation: Eur Urol. 2006 Oct;50(4):832-7
references.pmid: 16750292
references.citation: BJU Int. 2012 Apr;109(7):E21-2
references.pmid: 22414175
references.citation: Clin Microbiol Infect. 2012 Jun;18(6):575-81
references.pmid: 21958149
references.citation: Eur Urol. 2008 Dec;54(6):1270-86
references.pmid: 18423974
references.citation: J Urol. 2013 Apr;189(4):1326-31
references.pmid: 23041343
references.citation: Urology. 2011 May;77(5):1035-41
references.pmid: 21420152
references.citation: Eur Urol. 2013 Mar;63(3):521-7
references.pmid: 22704727
references.citation: Clin Infect Dis. 2012 May;54(10):1406-12
references.pmid: 22419681
references.citation: Int J Antimicrob Agents. 2000 Aug;15(3):207-11
references.pmid: 10926443
references.citation: Urology. 2008 Feb;71(2):191-5
references.pmid: 18308081
references.citation: Dtsch Arztebl Int. 2011 Jun;108(24):415-23
references.pmid: 21776311